Skip to main content

Market Overview

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Share:
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents.

Fastenal shares dipped 6.7% to $69.73 on Thursday.

Here are some other stocks moving in today's mid-day session.

Gainers

  • Rallybio Corporation (NASDAQ: RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
  • Rent the Runway, Inc. (NASDAQ: RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance.
  • Eliem Therapeutics, Inc. (NASDAQ: ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement.
  • Akanda Corp. (NASDAQ: AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.
  • Candel Therapeutics, Inc. (NASDAQ: CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.
  • Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
  • Selina Hospitality PLC (NASDAQ: SLNA) rose 21.1% to $0.0923.
  • Globavend Holdings Limited (NASDAQ: GVH) climbed 16.8% to $1.68.
  • Janux Therapeutics, Inc. (NASDAQ: JANX) gained 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.
  • SciSparc Ltd. (NASDAQ: SPRC) shares rose 15.3% to $1.9357.
  • Gyre Therapeutics, Inc. (NASDAQ: GYRE) gained 14.6% to $15.91.
  • AnaptysBio, Inc. (NASDAQ: ANAB) climbed 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.
  • Verb Technology Company, Inc. (NASDAQ: VERB) gained 10.4% to $0.2010 after gaining 4% on Wednesday.
  • GigaCloud Technology Inc. (NASDAQ: GCT) rose 10.2% to $34.18.
  • Nurix Therapeutics, Inc. (NASDAQ: NRIX) gained 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.
  • StepStone Group LP (NASDAQ: STEP) rose 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.

Losers

  • Aptevo Therapeutics Inc. (NASDAQ: APVO) shares fell 58% to $1.01 after the company priced its $4.6 million public offering.
  • Enlivex Therapeutics Ltd. (NASDAQ: ENLV) fell 54.5% to $1.81. The company announced topline results of its Phase II trial evaluating Allocetra in sepsis.
  • AVITA Medical, Inc. (NASDAQ: RCEL) fell 28.6% to $10.31 after the company announced an update to its expected commercial revenue for the first quarter of 2024. BTIG downgraded the stock from Buy to Neutral.
  • Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH) fell 19% to $0.3723.
  • Globe Life Inc. (NYSE: GL) fell 14.6% to $89.65.
  • The Lovesac Company (NASDAQ: LOVE) shares fell 14.3% to $20.00 after the company reported worse-than-expected fourth-quarter results and issued first-quarter guidance.
  • Globe Life Inc. (NYSE: GL) fell 13.7% to $90.56.
  • Meiwu Technology Company Limited (NASDAQ: WNW) shares declined 12.4% to $1.1601 after jumping around 32% on Wednesday.
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) fell 12% to $0.7660 after declining 14% on Wednesday. Acorda Therapeutics recently commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.
  • CarMax, Inc. (NYSE: KMX) fell 11.7% to $70.02 after the company reported lower-than-expected fourth-quarter earnings.
  • VBI Vaccines Inc. (NASDAQ: VBIV) dipped 11.3% to $0.5641.
  • Nikola Corporation (NASDAQ: NKLA) fell 11.3% to $0.8680. On April 9, Wolfe Research analyst Scott Group initiated coverage on Nikola with a Peer Perform rating.
  • Marin Software Incorporated (NASDAQ: MRIN) declined 10.8% to $0.5798.
  • SolarBank Corporation (NASDAQ: SUUN) fell 9.3% to $5.29. SolarBank closed purchase of 3.15 MW solar project in New York from Storke Renewable.
  • Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 9.1% to $2.29.
  • 9F Inc. (NASDAQ: JFU) fell 8.8% to $2.7046.
  • iCoreConnect Inc. (NASDAQ: ICCT) shares fell 8.5% to $1.55 after jumping over 50% on Wednesday.
  • ClearOne, Inc. (NASDAQ: CLRO) declined 8.3% to $1.00. The company recently reported fourth-quarter financial results.
  • Nyxoah S.A. (NASDAQ: NYXH) fell 7.3% to $9.83
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) fell 6.2% to $0.8164.
  • Walker & Dunlop, Inc. (NYSE: WD) fell 5.3% to $87.71 after Wedbush downgraded the stock from Outperform to Neutral and lowered its price target from $130 to $95.

 

Now Read This: Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

 

Related Articles (ACOR + AIH)

View Comments and Join the Discussion!

Posted-In: Mid-Day MoversNews Penny Stocks Small Cap Intraday Update Markets Movers Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com